To Our Shareholders and Friends:
In the life of every young development company comes a turning-point year—a year of significant milestones that both accelerate and validate its strategy. I believe 2008 was that year for Cougar Biotechnology. Driven by the performance of our lead product candidate, CB7630 (abiraterone acetate), Cougar became a Phase III company.

In April 2008, we began enrolling patients in the first Phase III clinical trial in our history, investigating CB7630’s use for advanced prostate cancer in patients who have failed chemotherapy. This is an especially notable achievement considering that we accomplished this milestone approximately 2 1/2 years after starting the Phase I clinical trial of CB7630.